Multiple Myeloma Support + Trials

What's the purpose of this trial?

This phase 1 trial is testing how well combinations of PVX-410, Citarinostat and Lenalidomide work in treating moderate/high risk Smoldering Myeloma. It will also evaluate what doses of these combinations are the safest and work the best.

This trial is currently open and accepting patients.

What's being studied?

Citarinostat is an HDAC inhibitor, a drug that can block proteins that tell cancer cells to grow and divide, which can cause cell death.
Hiltonol (Poly ICLC) is a medicine that helps the immune system cooperate and respond better to the vaccine, called an immunostimulant.
Lenalidomide is an immunomodulatory drug that may help the immune system kill cancer cells. It may also prevent the growth of new blood vessels that tumors need to grow.
PVX-410 is a cancer vaccine that is intended to induce a T cell-mediated immune response against the myeloma. The FDA (the U.S. Food and Drug Administration) has not approved PVX-410 as a treatment for any disease.

What will happen during the trial?

This trial is non-randomized, which means you will be assigned into one of two different groups, and this will determine which study drugs you will receive.

This trial is open label, which means both you and the researchers running the study will know which group you are placed in, and what drugs you will be receiving.

For both groups, this study is organized into screening period where you will undergo lab testing and tissue typing, the treatment period, and followup.

GROUP 1: PVX-410, Hiltonol, Citarinostat
GROUP 2: PVX-410, Hiltonol, Citarinostat, and Lenalidomide

During the first three months, both groups will receive biweekly injections of PVX-410 and Hiltonol given together, and take Citarinostat orally on days 1-21 of each 28 day cycle.

During the first three months, Group 2 will additionally receive Lenalidomide orally on days 1-21 of each 28 day cycle.

Once the initial three months have been completed, patients will receive followup doses of PVX-410 at 1, 2, 3, 6 and 9 months afterwards.

There are two experimental arms to this study. One arm is evaluating the combination of PVX-410 and Citarinostat. The other arm is a triplet combination evaluation of PVX-410 with Citarinostat and Lenalidomide.

This is a non-randomized study so you will know which arm you would be participating in if you are eligible for the study.

Experimental Arm 1: PVX-410 + Citarinostat

6 biweekly doses of PVX-410 - (0.8 mg/peptides) via subcutaneous injection
6 biweekly doses of Hiltonol - (1 mg) Intramuscular injection given at the time of PVX-410 administration (this drug is administered as an adjuvant to PVX-410 to help boost the patient’s immune response to the vaccine)
3 monthly cycles of Citarinostat - (180 mg) administered orally once daily on days 1-21 every 28 day cycle
This will be followed by a dose of PVX-410 at month 1, 2, 3, 6, and 9 follow-up visits

Experimental Arm 2: PVX-410 + Citarinostat + Lenalidomide

6 biweekly doses of PVX-410 - (0.8 mg) via subcutaneous injection
6 biweekly doses of Hiltonol - (1 mg) Intramuscular injection given at the time of PVX-410 administration
3 monthly cycles of Citarinostat - (180 mg) administered orally once daily on days 1-21 every 28 day cycle
3 monthly cycles of Lenalidomide - (25 mg) administered orally once daily on days 1-21 every 28 day cycle
This will be followed by a dose of PVX-410 at month 1, 2, 3, 6, and 9 follow-up visits

How long will I be in the study?

If you qualify and choose to participate, your total length of time in the study, including the screening, dosing period(s), and follow-up periods, will be about 16 months.

This study includes four periods:

Screening:The screening period, begins after you sign the informed consent form. It includes an exam and lab tests as well as tissue typing to evaluate whether or not you qualify for the clinical trial. The screening period may last about 28 days and will end with notification of whether or not you are qualified for the clinical trial.
Treatment:If you are accepted into the trial and choose to participate, you will be treated with the study drug. Detailed information about the duration, dosing and testing procedures during the treatment period and end of treatment visit will be explained by the study doctor.
Follow-up:following the end of active treatment you will have an additional visit with your doctor.

See if you qualify

Additional Trial Information

Phase 1

Enrollment: 20 patients (estimated)

Need Help?

Interested in joining or learning more about this trial?

(888) 828-2206

I'm Interested

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required. Create your account or call us today for help (888) 828-2206.

You may be eligible to participate in this study if you:

Are at least 18 years old.
Have smoldering multiple myeloma
Are at higher than average risk of progression to active multiple myeloma (classified as having more than 2 risk factors)
Has a life expectancy of greater than 6 months
Are HLA-A2+ (HLA testing is a way to determine your tissue type. Every patient has a tissue type. You need to be A2+ to participate in this study)
Cannot have received previous treatment with a HDAC inhibitor, including Citarinostat

View Additional Criteria

Inclusion Criteria:

Patient has confirmed SMM according to a definition derived from the International Myeloma Working Group (IMWG) definition (International Working Group, 2003): serum M-protein ≥3 g/dL or BMPC >10%, or both, along with normal organ and marrow function (CRAB) within 4 weeks before baseline.
- C: Absence of hypercalcemia, evidenced by a calcium <10.5 mg/dL.
- R: Absence of renal failure, evidenced by a creatinine < 1.5 mg/dL (177 µmol/L) or calculated creatinine clearance (using the Modification of Diet in Renal Disease [MDRD] formula) >50 mL/min.
- A: Absence of anemia, evidenced by a hemoglobin >10 g/dL.
- B: Absence of lytic bone lesions on standard skeletal survey.
Patient is at higher than average risk of progression to active MM, defined as having 2 or more of the following features:
- Serum M-protein ≥3 g/dL.
- BMPC >10%.
- Abnormal serum FLC ratio (0.26-1.65).
Patient is aged 18 years or older.
Patient has a life expectancy of greater than 6 months.
Patient is HLA-A2+
Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Patient has adequate bone marrow function, evidenced by a platelet count ≥75×109/L and an absolute neutrophil count (ANC) ≥1.0×109/L within 2 weeks before baseline.
Patient has adequate hepatic function, evidenced by a bilirubin ≤2.0 mg/dL and an alanine transaminase (ALT), and aspartate transaminase (AST) ≤2.5×ULN within 2 weeks before baseline.
If of child-bearing potential, patient agrees to use adequate birth control measures during study participation.
If a female of child-bearing potential , patient has negative serum pregnancy test results within 2 weeks before baseline and is not lactating.
If assigned to receive lenalidomide and a female of reproductive potential, must adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program.
If assigned to receive lenalidomide, patient must be registered into the mandatory Revlimid REMS® program and be willing and able to comply with the requirements of the REMS® program.
Patient (or his or her legally accepted representative) has provided written informed consent to participate in the study.
Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.

Exclusion Criteria:

Patient has symptomatic MM, as defined by any of the following:
- Lytic lesions or pathologic fractures.
- Anemia (hemoglobin <10 g/dL).
- Hypercalcemia (corrected serum calcium > 11.5 mg/dL).
- Renal insufficiency (creatinine > 1.5 mg/dL).
- Other: symptomatic hyperviscosity, amyloidosis.
Patient has a history of a prior malignancy within the past 3 years (excluding resected basal cell carcinoma of the skin or in situ cervical cancer).
Patient has abnormal cardiac status, evidenced by any of the following:
- New York Heart Association (NYHA) stage III or IV congestive heart failure (CHF).
- Myocardial infarction within the previous 6 months.
- Symptomatic cardiac arrhythmia requiring treatment or persisting despite treatment.
Patient is receiving any other investigational agent.
Patient has a current active infectious disease or positive serology for human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), or hepatitis A virus (HAV).
Patient has a history of or current auto-immune disease.
Patient has been vaccinated with live attenuated vaccines within 4 weeks before study vaccination.
Any previous treatment with a HDAC inhibitor, including Citarinostat.
Had involvement in the planning and/or conduct of the study by association with the Sponsor, study drug supplier(s) or study center or was previously enrolled in the present study.
Current or prior use of immunosuppressive medication within 28 days before the first dose of treatment, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid.
Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3 electrocardiograms (ECGs) using Frediricia's Correction.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, active peptic ulcer disease or gastritis, active bleeding diatheses, or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the patient to give written informed consent
Known history of previous clinical diagnosis of tuberculosis.

What's the purpose of this trial?

What's being studied?

What will happen during the trial?

Additional Trial Information

You may be able to join this trial if you:

Trial Locations

All Trial Locations

Georgia

Winship Cancer Institute of Emory University
Atlanta, GA

Not Yet Accepting

Massachusetts

Massachusetts General Hospital
Boston, MA

Open and Accepting

Beth Israel Deaconess Medical Center
Boston, MA

Open and Accepting

Dana-Farber Cancer Institute
Boston, MA

Open and Accepting

New York

Weill Cornell Medicine
New York, NY

Not Yet Accepting

North Carolina

Duke Cancer Center Duke University Medical Center
Durham, NC

Open and Accepting

Ohio

University Hospitals Seidman Cancer Center at UH Case Medical
Cleveland, OH

Open and Accepting

Trial Links

What Are Vaccines and How Do They Work in Myeloma?

What's the purpose of this trial?

What's being studied?

What will happen during the trial?

Additional Trial Information

You may be able to join this trial if you:

Trial Locations

All Trial Locations

Georgia

Winship Cancer Institute of Emory University Atlanta, GA

Not Yet Accepting

Massachusetts

Massachusetts General Hospital Boston, MA

Open and Accepting

Beth Israel Deaconess Medical Center Boston, MA

Open and Accepting

Dana-Farber Cancer Institute Boston, MA

Open and Accepting

New York

Weill Cornell Medicine New York, NY

Not Yet Accepting

North Carolina

Duke Cancer Center Duke University Medical Center Durham, NC

Open and Accepting

Ohio

University Hospitals Seidman Cancer Center at UH Case Medical Cleveland, OH

Open and Accepting

Trial Links

What Are Vaccines and How Do They Work in Myeloma?

Winship Cancer Institute of Emory University
Atlanta, GA

Massachusetts General Hospital
Boston, MA

Beth Israel Deaconess Medical Center
Boston, MA

Dana-Farber Cancer Institute
Boston, MA

Weill Cornell Medicine
New York, NY

Duke Cancer Center Duke University Medical Center
Durham, NC

University Hospitals Seidman Cancer Center at UH Case Medical
Cleveland, OH